Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
56 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Androgenic Alopecia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Androgenic Alopecia - Pipeline Review, H2 2014', provides an overview of the Androgenic Alopecia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Androgenic Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Androgenic Alopecia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Androgenic Alopecia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Androgenic Alopecia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Androgenic Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Androgenic Alopecia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Androgenic Alopecia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Androgenic Alopecia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Androgenic Alopecia Overview 7 Therapeutics Development 8 Pipeline Products for Androgenic Alopecia - Overview 8 Pipeline Products for Androgenic Alopecia - Comparative Analysis 9 Androgenic Alopecia - Therapeutics under Development by Companies 10 Androgenic Alopecia - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Androgenic Alopecia - Products under Development by Companies 13 Androgenic Alopecia - Companies Involved in Therapeutics Development 14 Allergan, Inc. 14 Dong-A Socio Group 15 Histogen, Inc. 16 Kasiak Research Pvt. Ltd. 17 Molplex Ltd. 18 Polichem S.A. 19 R-Tech Ueno, Ltd. 20 RepliCel Life Sciences, Inc. 21 RestorGenex Corporation 22 SWITCH Biotech LLC 23 Valeant Pharmaceuticals International, Inc. 24 Androgenic Alopecia - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 (finasteride + minoxidil) - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 bimatoprost - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 CB-0301 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 finasteride - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Hair Stimulating Complex (HSC) - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 RCH-01 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Refagro - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 RES-440 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 RK-023 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 SM-04554 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecule for Androgenic Alopecia - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecules for Androgenic Alopecia - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Androgenic Alopecia - Recent Pipeline Updates 51 Androgenic Alopecia - Dormant Projects 54 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 56 Disclaimer 56
List of Tables Number of Products under Development for Androgenic Alopecia, H2 2014 8 Number of Products under Development for Androgenic Alopecia - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Androgenic Alopecia - Pipeline by Allergan, Inc., H2 2014 14 Androgenic Alopecia - Pipeline by Dong-A Socio Group, H2 2014 15 Androgenic Alopecia - Pipeline by Histogen, Inc., H2 2014 16 Androgenic Alopecia - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 17 Androgenic Alopecia - Pipeline by Molplex Ltd., H2 2014 18 Androgenic Alopecia - Pipeline by Polichem S.A., H2 2014 19 Androgenic Alopecia - Pipeline by R-Tech Ueno, Ltd., H2 2014 20 Androgenic Alopecia - Pipeline by RepliCel Life Sciences, Inc., H2 2014 21 Androgenic Alopecia - Pipeline by RestorGenex Corporation, H2 2014 22 Androgenic Alopecia - Pipeline by SWITCH Biotech LLC, H2 2014 23 Androgenic Alopecia - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014 24 Assessment by Monotherapy Products, H2 2014 25 Assessment by Combination Products, H2 2014 26 Number of Products by Stage and Target, H2 2014 28 Number of Products by Stage and Mechanism of Action, H2 2014 30 Number of Products by Stage and Route of Administration, H2 2014 32 Number of Products by Stage and Molecule Type, H2 2014 34 Androgenic Alopecia Therapeutics - Recent Pipeline Updates, H2 2014 51 Androgenic Alopecia - Dormant Projects, H2 2014 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.